ARCT - Arcturus Therapeutics GAAP EPS of -$0.32 beats by $0.54 revenue of $33.99M misses by $3.88M
2024-03-07 16:02:49 ET
More on Arcturus Therapeutics
- Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
- Arcturus: H1 2024 Rare Disease Drug Data On Deck
- Arcturus Therapeutics Q4 2023 Earnings Preview
- Arcturus gets EU orphan drug status for cystic fibrosis drug
- Seeking Alpha’s Quant Rating on Arcturus Therapeutics